Skip to main content
. 2021 Apr 30;7(4):e25075. doi: 10.2196/25075

Table 1.

Characteristics of outpatients with COVID-19 by assigned risk tier in a retrospective cohort from a telemedicine monitoring program in Atlanta, Georgia, with enrollment between March 24 and May 26, 2020.

Characteristic All patients (N=496) Tier 1a (n=237) Tier 2a (n=185) Tier 3a (n=74)
Age (years), mean (95% CI) 47.6 (46.3-48.9) 41.5 (39.8-43.2) 52.5 (50.6-54.4) 54.9 (51.4-58.4)
Days from first symptom to intake visit, mean (95% CI) 9.3 (8.5-10.0) 8.9 (8.2-9.7) 10.0 (8.4-11.6) 8.4 (6.9-9.8)
Days from COVID-19 test to intake visit, mean (95% CI) 3.7 (3.4-3.9) 3.9 (3.4-4.4) 3.5 (3.0-3.9) 3.3 (2.7-4.0)
Follow-up duration (days from intake), mean (95% CI) 13.1 (12.2-13.9) 9.5 (8.6-10.4) 16.3 (14.8-17.7) 16.7 (14.0-19.3)
Age category (years), n (%)

18-29 78 (15.7) 65 (27.4) 10 (5.4) 3 (4.1)
30-39 84 (16.9) 49 (20.7) 26 (14.1) 9 (12.2)
40-49 106 (21.4) 50 (21.1) 39 (21.1) 17 (23.0)
50-59 115 (23.2) 48 (20.3) 50 (27.0) 17 (23.0)
60-69 84 (16.9) 21 (8.9) 45 (24.3) 18 (24.3)
≥70 29 (5.8) 4 (1.7) 15 (8.1) 10 (13.5)
Race, n (%)

Black 252 (50.8) 109 (46.0) 102 (55.1) 41 (55.4)
White 97 (19.6) 47 (19.8) 36 (19.5) 14 (18.9)
Other 147 (29.6) 81 (34.2) 47 (25.4) 19 (25.7)
Gender, n (%)

Female 330 (66.5) 156 (65.8) 125 (67.6) 49 (66.2)
Male 166 (33.5) 81 (34.2) 60 (32.4) 25 (33.8)
Comorbidities, n (%)

Asthma 73 (14.7) 18 (7.6) 37 (20.0) 18 (24.3)
Cancer or malignancy 37 (7.5) 9 (3.8) 21 (11.4) 7 (9.5)
Chronic obstructive pulmonary disease 5 (1.0) 0 (0) 4 (2.2) 1 (1.4)
Coronary artery disease 24 (4.8) 1 (0.4) 11 (5.9) 12 (16.2)
Diabetes 69 (13.9) 10 (4.2) 35 (18.9) 24 (32.4)
Drug abuse or addiction 4 (0.8) 0 (0) 4 (2.2) 0 (0)
Heart failure 10 (2.0) 2 (0.8) 4 (2.2) 4 (5.4)
Hypertension 175 (35.3) 42 (17.7) 91 (49.2) 42 (56.8)
Immune suppression 30 (6.0) 9 (3.8) 11 (5.9) 10 (13.5)
Lung disease 17 (3.4) 3 (1.3) 9 (4.9) 5 (6.8)
Reported obesityb 147 (29.6) 52 (21.9) 63 (34.1) 32 (43.2)
Corrected obesityc 212 (42.7) 87 (36.7) 85 (45.9) 40 (54.1)
Renal disease 16 (3.2) 3 (1.3) 6 (3.2) 7 (9.5)
Number of diagnoses, n (%)

0 (healthy) 174 (35.1) 129 (54.4) 35 (18.9) 10 (13.5)
1 158 (31.9) 81 (34.2) 65 (35.1) 12 (16.2)
2 91 (18.3) 19 (8.0) 48 (25.9) 24 (32.4)
≥3 73 (14.7) 8 (3.4) 37 (20.0) 28 (37.8)
Ability to self-isolate safely, n (%)

Adequate 409 (82.5) 205 (86.5) 156 (84.3) 48 (64.9)
Inadequate 9 (1.8) 1 (0.4) 3 (1.6) 5 (6.8)
Unknown 78 (15.7) 31 (13.1) 26 (14.1) 21 (28.4)
Severity of symptoms, n (%)

None or mild 316 (63.7) 204 (86.1) 102 (55.1) 10 (13.5)
Moderate 134 (27.0) 18 (7.6) 69 (37.3) 47 (63.5)
Severe 9 (1.8) 0 (0) 0 (0) 9 (12.2)
Unknown 37 (7.5) 15 (6.3) 14 (7.6) 8 (10.8)
Symptoms course, n (%)

Improving 264 (53.2) 156 (65.8) 90 (48.6) 18 (24.3)
Stable 155 (31.3) 61 (25.7) 65 (35.1) 29 (39.2)
Worsening 31 (6.3) 0 (0) 14 (7.6) 17 (23.0)
Unknown 46 (9.3) 20 (8.4) 16 (8.6) 10 (13.5)

aRisk tiers: Tier 1 = low risk, Tier 2 = intermediate risk, and Tier 3 = high risk (Multimedia Appendix 2).

bBMI ≥30 recorded in Virtual Outpatient Monitoring Clinic (VOMC) intake note by provider; BMI is calculated as weight in kilograms divided by height in meters squared.

cBMI ≥30 determined by height and weight data in electronic medical record or recorded in VOMC intake note; BMI is calculated as weight in kilograms divided by height in meters squared.